DESTINY-Breast06: Demographics and Baseline Characteristics (March 18, 2024 DCO Date)1
Patient Disposition1
Patient Disposition1
Patient Disposition1
At DCO, 119 patients (14.0%) remained on treatment: 89 (20.5%) T-DXd and 30 (7.2%) TPC. Median duration of follow up: 18.2 months (ITT)1
Baseline Characteristics1
Patient Demographics and Key Baseline Characteristics1
Patient Demographics and Key Baseline Characteristics1
*HER2-low status defined at randomization per IRT data, and HER2-ultralow status defined per central laboratory testing data. With mis-stratification, the combined sample size of these two populations may not match the ITT total.
†n=14 patients had missing ECOG PS status at baseline.
‡n=2 patients in the ITT (1 per treatment group) were found to have HER2 IHC 0 with absent membrane staining per central laboratory testing.
§Patients with ER−/PR− status were excluded from the study; however, n=1 patient with ER–/PR– status was randomized in error.
¶Defined as relapse while on the first 2 years of adjuvant endocrine therapy, or progressive disease within the first 6 months of first-line endocrine therapy for metastatic breast cancer.
Prior Therapies1
Prior Therapies1
Prior Therapies1
*HER2-low status determined per IRT data, and HER2-ultralow status determined per central laboratory data.
†Other targeted therapies were mTORi (23.8%), PIK3CAi (4.2%), or PARPi (0.9%) in the ITT population.
‡Approximately 30% of the patient population had de-novo metastatic disease and were not included in this category.
Abbreviations
CDK4/6i = cyclin-dependent kinase 4/6 inhibitor
;DCO = data cut-off
;ECOG = Eastern Cooperative Oncology Group
;ER = estrogen receptor
;ET = endocrine therapy
;HER2 = human epidermal growth factor receptor 2
;IHC = immunohistochemistry
;ISH = in situ hybridization
;ITT = intent-to-treat
;mTORi = mammalian target of rapamycin inhibitor
;PARPi = poly-adenosine diphosphate ribose polymerase inhibitor
;PD = progressive disease
;PIK3CAi = phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha inhibitor
;PR = progesterone receptor
;PS = performance status
;T-DXd = trastuzumab deruxtecan
;TPC = treatment of physician's choice
References
1. Curigliano G, Hu X, Dent R, et al. Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06. Presented at 2024 ASCO Annual Meeting; May 31-June 4, 2024; Chicago, Illinois. Presentation LBA1000.
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
To help us improve our content for health care professionals, please take this short survey.
Document ID: c791d159-0a5c-4180-b38f-cd5e26050804
Last updated: 28-June-2024
©2023 AstraZeneca. All rights reserved.